Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Apitope Led Consortium Receives up to €6M FP7 Funding

Published: Thursday, January 09, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Consortium receives FP7 Health Innovation funding to develop Graves’ disease therapeutic vaccine.

Apitope has announced that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 (FP7) Health Innovation funding by the European Commission to develop its Graves’ disease therapeutic vaccine, including a Phase I first-in-man study in Graves’ disease patients.

Graves’ disease is an immune system disorder that eventually results in the overproduction of thyroid hormones (hyperthyroidism).

While a number of disorders may result in hyperthyroidism, Graves' disease is the most common cause affecting 2% of the female population.

Symptoms of hyperthyroidism can include increased heart rate, muscle weakness, disturbed sleep, and irritability. Patients may also develop bulging eyes (proptosis). The disease affects multiple systems of the body, including the skin, heart, circulation and nervous system.

Apitope’s antigen-specific disease modifying peptide therapy uses epitopes designed to shut down the abnormal immune responses to the causative agent in a highly selective manner, re-instating the normal immune balance, thereby avoiding global immune suppression.

As a result, the peptides taken into clinical evaluation by Apitope offer the potential to have limited side effects and a good probability of efficacy.

Dr. Keith Martin, CEO of Apitope stated: “Graves’ Disease is a disease with serious implications particularly for those with Graves’ orbitopathy who are at risk of blindness. Current treatments for this disease may result in abnormally low thyroid activity levels, requiring further medications, and do not treat the fundamental cause of Graves’ disease nor reduce the long term cardiac risks. This funding will allow a team of experts to develop a much needed therapy that may address the cause of this serious condition rather than simply treating the symptoms and removing the need for other medications.”

Professor Neil Williams, CSO of KWS BioTest said: “This is a really exciting approach to the treatment of an important human disease, which builds on the successes that Apitope has seen in its MS programme. We are looking forward to applying our expertise in the preclinical immunology and inflammation areas to help drive the project forwards into the clinic. The award of the EU grant helps to cement the close drug discovery partnership in the consortium.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Grants Orphan Status for ATX-F8-117 in the US
Prevention or treatment of haemophilia A patients with inhibitors or at risk of developing inhibitors to Factor VIII.
Saturday, June 13, 2015
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!